PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 6544808

The dexamethasone suppression test during bereavement.

T R Kosten·S Jacobs·J W Mason
View original source ↗Export metadata ↓

Abstract

The dexamethasone suppression test (DST) was given to 13 elderly grieving subjects having a major depressive disorder. Forty-six per cent had some predisposition for depression. All had a post-DST, 4:00 p.m. serum cortisol below 5 micrograms/dl, but these cortisols correlated with Hamilton Depression scores (r = .59, p less than .05).

Explore related subjects

Depressive DisorderDexamethasoneFemaleGriefHumansHydrocortisoneMaleMiddle AgedPsychiatric Status Rating ScalesJournal ArticleResearch Support, Non-U.S. Gov'tResearch Support, U.S. Gov't, P.H.S.

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

T R Kosten, S Jacobs, J W Mason. 1984. The dexamethasone suppression test during bereavement.. https://doi.org/10.1097/00005053-198406000-00007

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Psychological morbidity and female urinary incontinence.

Female urinary incontinence is a common yet distressing condition. It affects women of all ages, but is especially common in the elderly. Its prevalence ranges from 15 to 55%, depending on age and population studied. Despite the ubiquity of female urinary incontinence, many incontinent women do not voice their suffering, and urinary incontinence has therefore been dubbed 'the silent epidemic'. The physical impact and social isolation associated with urinary incontinence lead to impairment of quality of life and psychological well-being. It is the aim of this review to discuss the epidemiology and psychological impact of urinary incontinence. The recognition and management of incontinence-related psychological morbidity are also explored.

Depressive Disorder↗
PubMed2007

Vagus nerve stimulation therapy in depression and epilepsy: therapeutic parameter settings.

Vagus nerve stimulation (VNS) therapy is an effective adjunctive treatment for chronic or recurrent treatment-resistant depression in adults, and for pharmacoresistant epilepsy in adults and adolescents. VNS therapy is administered through an implanted pulse generator that delivers programmed electrical pulses through an implanted lead to the left vagus nerve. Programmable pulse parameters include output current, frequency, pulse width, and ON/OFF times. Within a range of typical values, individual patients respond best to different combinations of parameter settings. The physician must identify the optimum settings for each patient while balancing the goals of maximizing efficacy, minimizing side effects, and preserving battery life. Output current is gradually increased from 0.25 mA to the maximum tolerable level (maximum, 3.5 mA); typical therapeutic settings range from 1.0 to 1.5 mA. Greater output current is associated with increased side effects, including voice alteration, cough, a feeling of throat tightening, and dyspnea. Frequency is typically programmed at 20 Hz in depression and 30 Hz in epilepsy. Pulse width is typically 250 or 500 micros. The recommended initial ON time is 30 s, followed by 5 min OFF; OFF time > ON time is recommended. As with pharmacotherapy, VNS therapy must be adjusted in a gradual, systematic fashion to individualize therapy for each patient.

Depressive Disorder↗